Searchable abstracts of presentations at key conferences in endocrinology

ea0016p171 | Comparative endocrinology | ECE2008

Effects of dietary advanced glycation end products on endocrine and metabolic parameters of women with polycystic ovarian syndrome

Tantalaki Evangelia , Piperi Christina , Koulouri Katerina , Livadas Sarantis , Argyrakopoulou Giouli , Economou Fragkiskos , Mpoutzios Giorgos , Papavassiliou Athanasios , Diamanti-Kandarakis Evanthia

In female rats, diet enriched in advanced glycation end products (AGEs) has been associated with increased serum testosterone levels and deposition of dietary glycotoxins in ovarian tissue.Women with PCOS present increased serum AGE levels, which are acutely elevated after intake of a single meal high in AGE content. In this study the effects of a hypocaloric diet and an AGE-enriched hypocaloric diet were investigated, on the endocrine and metabolic prof...

ea0094p85 | Neuroendocrinology and Pituitary | SFEBES2023

Development of an optimal imaging pathway for management of somatotroph tumors in acromegaly

Haberbosch Linus , Macfarlane James , Koulouri Olympia , Gillett Dan , Spranger Joachim , Mai Knut , Cheow Heok , Jones Jonathan , Strasburger Christian , Gurnell Mark

Background: Acromegaly is associated with significant excess morbidity and mortality. Surgery and radiotherapy (including radiosurgery) aim to reduce the burden of growth hormone excess while preserving normal pituitary function, but their effective deployment is dependent on high quality imaging that allows accurate localization of site(s) of active de novo or residual/recurrent disease. Despite the existence of several comprehensive guidelines on the managem...

ea0082p25 | Poster Presentations | SFEEU2022

An exception to the rule: transformation of an adrenocortical lesion with benign radiological characteristics

MacFarlane James , Lau Eunice , Palma August , Koulouri Olympia , Harper Ines , Stokes Victoria , Challis Ben , Shaw Ashley , Aloj Luigi , Mendichovszky Iosif , Cheow Heok , Bashari Waiel , Gurnell Mark , Casey Ruth

Section 1: Case history: A 69 year old man with chronic obstructive pulmonary disease was admitted with acute onset shortness of breath. A CT pulmonary angiogram revealed no focal lung abnormality but identified an incidental 40 x 32 mm left-sided adrenal lesion. An unenhanced CT, undertaken to characterise the lesion, showed a homogeneous, well-circumscribed appearance with a radiodensity of 4 Hounsfield units. Prior to involvement of the Endocrinology team, a dedicated MRI w...

ea0086oc3.1 | Reproductive and Neuroendocrinology | SFEBES2022

Depot somatostatin receptor ligand therapy reverses tissue thyrotoxicosis in thyrotropinomas and aids microadenoma localization via 11C-Methionine PET

Koulouri Olympia , MacFarlane James , Bashari Waiel , Gillett Daniel , Senanayake Russell , Halsall David , Oddy Sue , Powlson Andrew , Serban Laura , Moran Carla , Schoenmakers Nadia , Chatterjee Krishna , Gurnell Mark

Context: Surgery is the first-line treatment option for thyrotropinomas, but medical therapy with somatostatin receptor ligands (SRL) may be used as neoadjuvant treatment and to facilitate safe surgery.Objectives: To determine the extent to which neoadjuvant SRL (i) corrects clinical, laboratory and tissue hyperthyroidism in thyrotropinomas, (ii) induces tumour shrinkage in macroadenomas, and (iii) aids microadenoma detection by 11C-methionine...

ea0065op6.1 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Extended TSS (guided by 11C-methionine PET + MRI (Met-PET/MRCR)) can be an effective treatment option for patients with persistent acromegaly due to previously deemed unresectable lateral disease

Bashari Waiel A , Senanayake Russell , Fernandez-Pombo Antia , Gillett Daniel , Koulouri Olympia , Powlson Andrew , Cheow Heok , Mendichovszky Iosif , Kolias Angelos , Tysome James , Santarius Thomas , Mannion Richard , Gurnell Mark

Objective: To determine if an extended lateral approach to trans-sphenoidal surgery (TSS), guided by 11C-Methionine PET/CT co-registered with volumetric MRI (Met-PET/MRCR), can lead to remission in patients with persistent acromegaly due to post-operative lateral/para-sellar tumour remnants.Methods: We identified eight patients with persistent acromegaly following primary intervention [TSS ± medical therapy ± radiotherapy ...

ea0044p151 | Neuroendocrinology and pituitary | SFEBES2016

MicroTSHoma: an emerging clinical entity with ‘atypical’ biochemical features and often ‘normal’ imaging characteristics on MRI

Koulouri Olympia , Moran Carla , Heard Sarah , Lyons Greta , Smith Rob , Aigbirhio Franklin , Antoun Nagui , Cheow Heok , Halsall David , Chatterjee Krish , Gurnell Mark

Background: Heightened awareness, as well as frequent thyroid function testing, have contributed to a recent rise in the incidence of thyrotropinomas. Microadenomas are now increasingly being recognized. The classical textbook description of thyrotropinomas is based on historically reported features in patients who typically had large/invasive lesions. The phenotype of microTSHomas could therefore differ.Methods: We reviewed the records of all TSHomas re...

ea0039oc5.5 | Oral Communications 5 | BSPED2015

A novel, missense, mutation (P81R) in the TRH receptor gene in congenital central hypothyroidism

Koulouri Olympia , Nicholas Adeline , Schoenmakers Erik , Mokrosinski Jacek , Lane Frances , Cole Trevor , Kirk Jeremy , Farooqi Sadaf , Chatterjee Krishna , Gurnell Mark , Schoenmakers Nadia

Background: Congenital, isolated, central, hypothyroidism (CCH), is rare and evades diagnosis on TSH-based congenital hypothyroidism screening programmes in the UK. Genetic ascertainment is therefore paramount in enabling prompt diagnosis and treatment of familial cases. Recognised causes include TSHB and IGSF1 gene defects, with only two previous reports of biallelic, highly disruptive (nonsense; R17X, in-frame deletion and missense; p.S115-T117del+T118), mu...

ea0038oc5.2 | Thyroid and parathyroid | SFEBES2015

A novel, missense, mutation (P81R) in the TRH receptor gene in congenital central hypothyroidism

Koulouri Olympia , Nicholas Adeline , Schoenmakers Erik , Mokrosinski Jacek , Lane Frances , Cole Trevor , Kirk Jeremy , Farooqi Sadaf , Chatterjee Krishna , Gurnell Mark , Schoenmakers Nadia

Background: Congenital, isolated, central, hypothyroidism (CCH), is rare and evades diagnosis on TSH-based congenital hypothyroidism screening programmes in the UK. Genetic ascertainment is therefore paramount in enabling prompt diagnosis and treatment of familial cases. Recognised causes include TSHB and IGSF1 gene defects, with only two previous reports of biallelic, highly disruptive (nonsense; R17X, in-frame deletion and missense; p.S115-T117del+T118), mu...

ea0037oc1.4 | Adrenal 1 | ECE2015

11C-metomidate PET-CT in primary aldosteronism: five possible indications for a non-invasive alternative to adrenal vein sampling

Powlson Andrew S , Koulouri Olympia , Azizan Elena , Maniero Carmela , Taylor Kevin , Aigbirhio Franklin , Koo Brendan , Cheow Heok K , Buscombe John , Gurnell Mark , Brown Morris J

Background: Adrenal vein sampling (AVS) remains the gold-standard for distinguishing unilateral and bilateral disease in primary aldosteronism (PA). However, it is invasive, technically demanding, and may yield inconclusive or equivocal results. 11C-Metomidate PET-CT (11C-MTO-PET-CT) is a non-invasive alternative to AVS for localising unilateral aldosterone-producing adenomas (APAs).Methods/patients: We report a retrospective analys...

ea0037gp.20.08 | Pituitary – Hypopituitarism | ECE2015

‘Pseudo-resistance' in macroprolactinomas treated with dopamine agonists; recognising delayed radiological response and a role for 11C-methionine PET-CT in guiding management

Powlson Andrew S , Koulouri Olympia , Steuwe Andrea , Gillett Daniel , Heard Sarah , Hoole Andrew , Scott Miriam , Challis Benjamin G , Antoun Nagui , Cheow Heok K , Mannion Richard J , Gurnell Mark

Background: Endocrine Society guidelines classify macroprolactinomas as ‘resistant’ if there is failure to normalise prolactin, or to achieve radiological tumour shrinkage of >50%, on standard doses of dopamine agonist. In this context, escalation of treatment to maximal tolerable doses and/or referral for surgery is advised. However, we have recently observed several ‘discordant responders’, where tumour shrinkage lags significantly (>6 months) beh...